Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis b virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 475-485

  Hsieh, Yi Hsuan ^a   Su, Ih Jen ^b,e   Yen, Chia Jui ^c   Tsai, Ting Fen ^d   Tsai, Hung Wen ^c   Tsai, Han Ni ^a   Huang, Yu Jun ^a   Chen, Yen Yu ^a   Ai, Yu Lin ^a   Kao, Lin Yuan ^c   Hsieh, Wen Chuan ^b   Wu, Han Chieh ^b   Huang, Wenya ^a,c,e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; NUCLEAR FACTOR Y; THIOREDOXIN INTERACTING PROTEIN; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER PREVENTION; CELL NUCLEUS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; G1 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE REPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; S PHASE CELL CYCLE CHECKPOINT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTANT PROTEINS; MUTATION; NUCLEAR PROTEINS; PEPTIDE HYDROLASES; PROTEIN PRECURSORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TATA BOX BINDING PROTEIN-LIKE PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84873562300     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs365     Document Type: Article

References (42)

1. Lee,Y.I. et al. (2001) The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem., 276, 16969-16977.
2. Klein,N.P. et al. (1997) Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol. Cell. Biol., 17, 6427-6436.
3. Doria,M. et al. (1995) The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J., 14, 4747-4757.
4. Lara-Pezzi,E. et al. (1998) The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sensitive pathway. EMBO J., 17, 7066-7077.
5. Tan,A. et al. (2008) Viral hepatocarcinogenesis: from infection to cancer. Liver Int., 28, 175-188.
6. Huang,S.N. et al. (1995) Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology, 21, 620-626.
7. Ibarra,M.Z. et al. (1989) Detection of proteins encoded by the pre-S region of hepatitis B virus in the sera of HBsAg carriers: relation to viral replication. Liver, 9, 153-158.
8. Fan,Y.F. et al. (2000) Identification of a pre-S2 mutant in hepatocytes expressing a novel marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol., 15, 519-528.
9. Fan,Y.F. et al. (2001) Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology, 33, 277-286.
10. Wang,H.C. et al. (2003) Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am. J. Pathol., 163, 2441-2449.
11. Su,I.J. et al. (2008) Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J. Gastroenterol. Hepatol., 23(8 Pt 1), 1169-1174.
12. Chen,B.F. et al. (2006) High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology, 130, 1153-1168.
13. Chen,C.H. et al. (2007) Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology, 133, 1466-1474.
14. Hsieh,Y.H. et al. (2004) Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis, 25, 2023-2032.
15. Wang,H.C. et al. (2005) Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology, 41, 761-770.
16. Hsieh,Y.H. et al. (2007) Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol. Cancer Res., 5, 1063-1072.
17. Tomoda,K. et al. (2002) The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J. Biol. Chem., 277, 2302-2310.
18. Tsai,H.W. et al. (2011) A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery. Cancer, 117, 2951-2960.
19. Ruggeri,M. (2012) Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag. Healthc. Policy, 5, 49-54.
20. Shen,F.C. et al. (2009) A pre-S gene chip to detect pre-S deletions in hepatitis B virus large surface antigen as a predictive marker for hepatoma risk in chronic hepatitis B virus carriers. J. Biomed. Sci., 16, 84.
21. Jeon,J.H. et al. (2005) Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res., 65, 4485-4489.
22. Butler,L.M. et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and downregulates thioredoxin. Proc. Natl. Acad. Sci. U.S.A., 99, 11700-11705.
23. Drummond,D.C. et al. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol., 45, 495-528.
24. Mann,B.S. et al. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 12, 1247-1252.
25. Moffat,J. et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell, 124, 1283-1298.
26. Wu,Y.F. et al. (2008) Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res., 68, 2033-2042.
27. Lobjois,V. et al. (2009) Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. Eur. J. Cancer, 45, 2402-2411.
28. Deroanne,C.F. et al. (2002) Histone deacetylases inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21, 427-436.
29. Yang,J.C. et al. (2009) Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology, 49, 1962-1971.
30. Calvis,D.F. et al. (2009) SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology, 137, 1816-1826.
31. Hsu,M.C. et al. (2008) Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Clin. Cancer Res., 14, 4045-4052.
32. Qin,J. et al. (2010) JAB1 expression is associated with inverse expression of p27(kip1) in hepatocellular carcinoma. Hepatogastroenterology., 57, 547-553.
33. Bhatnagar,N. et al. (2009) 3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev. Res. (Phila)., 2, 581-589.
34. Casto,B.C. et al. (2011) Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration. Anticancer Res., 31, 3279-3284.
35. Okuyama,H. et al. (2008) Thioredoxin and thioredoxin binding protein 2 in the liver. IUBMB Life, 60, 656-660.
36. Manni,I. et al. (2008) Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity. Mol. Biol. Cell, 19, 5203-5213.
37. Rahmani,M. et al. (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res., 65, 2422-2432.
38. Breinholt,V. et al. (1999) Chlorophyllin chemoprevention in trout initiated by aflatoxin B(1) bath treatment: An evaluation of reduced bioavailability vs. target organ protective mechanisms. Toxicol. Appl. Pharmacol., 158, 141-151.
39. Sporn,M.B. et al. (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc., 35, 1332-1338.
40. Homma,S. et al. (2009) Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res., 15, 3423-3432.
41. Lu,Y.S. et al. (2007) Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology, 46, 1119-1130.
42. Ho,E. et al. (2009) Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J. Nutr., 139, 2393-2396.